The British Journal of Clinical Pharmacology

Volume 56
2003

Published for
The British Pharmacological Society by
Blackwell Publishing

© 2003, Blackwell Publishing Ltd
9600 Garsington Road, Oxford OX4 2DQ
101 George Street, Edinburgh EH2 3ES
Commerce Place, 350 Main Street, Malden MA 02148, USA
550 Swanson St Carlton, South Victoria 3053, Australia

Other Editorial Offices:
Blackwell Munksgaard
1 Rosenørns Allè
PO Box 227
DK-1502 Copenhagen V
Denmark

Blackwell Verlag
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Publishing
10 rue Casimir Delavigne
75006 Paris
France

Blackwell Publishing KK
Healthcare Division
NK Bldg, 3F
2-8-12 Iwamotocho
Chiyodaku, Tokyo 101-0032
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/01 $15.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by SNP Best-set Typesetter Ltd., Hong Kong
Printed and Bound by The Charlesworth Group, Huddersfield

Contents

This article is considered particularly suitable for continuing medical education.

Volume 56, Number 1, July 2003

Editor's View

1 Features of this month's *Journal*: *J.K. Aronson*

Review

3 Angiotensin II dose–effect curves and Schild regression plots for characterization of different angiotensin II AT_1 receptor antagonists in clinical pharmacology: *G.G. Belz*

Pharmacodynamics

11 Effects of fluticasone *vs.* fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma: *G.P. Currie, S. Stenback & B.J. Lipworth*

18 Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk: *K. Aljazaf, T.W. Hale, K.F. Ilett, P.E. Hartmann, L.R. Mitoulas, J.H. Kristensen & L.P. Hackett*

Pharmacokinetics

25 Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya: *A.H. Thomson, G.O. Kokwaro, S.N. Muchohi, M. English, S. Mohammed & G. Edwards*

32 Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction: *J. Rengelshausen, C. Göggelmann, J. Burhenne, K.-D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack & W.E. Haefeli*

39 Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects: *G.M. Ferron, A. Patat, V. Parks, P. Rolan & S.M. Troy*

46 A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979): *S. Callies, D.P. de Alwis, A. Harris, P. Vasey, J.H. Beijnen, J.H. Schellens, M. Burgess & L. Aarons*

Pharmacokinetics and pharmacodynamics

57 Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan *vs.* dextrorphan using quinidine inhibition: *A.A. Moghadamnia, A. Rostami-Hodjegan, R. Abdul-Manap, C.E. Wright, A.H. Morice & G.T. Tucker*

Metabolism

68 CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy: *F.-X. Yan, M.C. Langub, M.A. Ihnen, C. Hornung, E. Juronen, M.K. Rayens, W.-M. Cai, P.J. Wedlund & P. Fanti*

Pharmacogenetics

78 Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates: *C. Balram, A. Sharma, C. Sivathasan & E.J.D. Lee*

Pharmacoepidemiology

84 Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics: *C.-C. Yang, S.S. Jick & M.A. Testa*

92 Antibiotic prescribing for children. Too much and too little? Retrospective observational study in primary care: *S. Ekins-Daukes, J.S. McLay, M.W. Taylor, C.R. Simpson & P.J. Helms*

Therapeutics

96 Development of a dosing strategy for enoxaparin in obese patients: *B. Green & S.B. Duffull*

104 Add-on therapy with montelukast or formoterol in patients with the glycine-16 β2-receptor genotype: *E.J. Sims, C.M. Jackson & B.J. Lipworth*

Short communications

112 Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus: *B.R. Ogutu, C.R.J.C. Newton, S.N. Muchohi, G.O. Otieno, G. Edwards, W.M. Watkins & G.O. Kokwaro*

120 The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6: *T. Prueksaritanont, B. Ma & N. Yu*

125 Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves: *S.W. Toennes, S. Harder, M. Schramm, C. Niess & G.F. Kauert*

131 Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects: *S.K. Gupta, P. Glue, S. Jacobs, D. Belle & M. Affrime*

Letter to the editor

135 Comparability of whole-blood and plasma clozapine and norclozapine concentrations: *R.J. Flanagan, B. Yusufi & T.R.E. Barnes*

Obituary

139 David Margerison Davies, 1923–2002: *H. de Glanville & R. Ferner*

Volume 56, Number 2, August 2003

Editor's View

141 Features of this month's *Journal*: *J.K. Aronson*

Review

143 British Journal of Clinical Pharmacology review series Clinical research methods in gastroenterology: *M.M. Walker & B.J.R. Whittle*

146 Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract: *M.W. James & C.J. Hawkey*

156 Gastric function measurements in drug development: *T. Pohle & W. Domschke*

Pharmacodynamics

165 A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects: *T. Sycha, B. Gustorff, S. Lehr, A. Tanew, H.-G. Eichler & L. Schmetterer*

Pharmacokinetics

173 Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients: *P.-H. Zingmark, M. Ekblom, T. Odergren, T. Ashwood, P. Lyden, M.O. Karlsson & E.N. Jonsson*

184 Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects: *K. Sathirakul, C. Chan, L. Teng, R.F. Bergstrom, K.P. Yeo & S.D. Wise*

188 Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil: *B. Shum, S.B. Duffull, P.J. Taylor & S.E. Tett*

198 Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine: *H. El-Eraky & S.H.L. Thomas*

205 Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients: *T. Ishibashi, Y. Yano & T. Oguma*

Pharmacokinetics and pharmacodynamics

214 Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients: *L. Renders, C.S. Haas, J. Liebelt, M. Oberbarnscheidt, H.O. Schöcklmann & U. Kunzendorf*

Short communications

220 A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment: *M.R. Shiran, J. Chowdry, A. Rostami-Hodjegan, S.W. Ellis, M.S. Lennard, M.Z. Iqbal, O. Lagundoye, N. Seivewright & G.T. Tucker*

225 Dose–response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation: *H.S. Tomlinson, S.A. Corlett & H. Chrystyn*

228 Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome: *C. Skarke, H. Schmidt, G. Geisslinger, J. Darimont & J. Lötsch*

232 The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects: *S. Palovaara, G. Tybring & K. Laine*

Case report

238 A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy: *F.C. Sasso, O. Carbonara, P.D. Micco, L. Coppola, R. Torella & A. Niglio*

240 Proceedings of the London Hypertension Society 20 May 2003

Volume 56, Number 3, September 2003

Editor's view

247 Features of this month's *Journal*: *J.K. Aronson*

Reviews

249 The clinical pharmacology of ageing: *C.G. Swift*

254 The cardiovascular system in the ageing patient: *A. Moore, A.A. Mangoni, D. Lyons & S.H.D. Jackson*

261 Clinical pharmacology of old age syndromes: *C. Broadhurst, K.C.M. Wilson, M.T. Kinirons, A. Wagg & J.K. Dhesi*

273 Diagnostic methods for *Helicobacter pylori* detection and eradication: *A.F. Goddard & R.P.H. Logan*

284 Determining small bowel integrity following drug treatment: *S. Smale & I. Bjarnason*

292 Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?: *S. Vožeh*

Pharmacokinetics and drug disposition

297 Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men: *J.O. Olubodun, H.R. Ochs, L.L. von Moltke, R. Roubenoff, L.M. Hesse, J.S. Harmatz, R.I. Shader & D.J. Greenblatt*

305 CYP2C8 and CYP3A4 are the principal enzymes involved in the human *in vitro* biotransformation of the insulin secretagogue repaglinide: *T.B. Bidstrup, I. Bjørnsdottir, U.G. Sidelmann, M.S. Thomsen & K.T. Hansen*

Pharmacogenetics

315 Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6: *T. Ohnuma, N. Shibata, Y. Matsubara & H. Arai*

Pharmacodynamics

321 Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans: *J. Graff, U. Klinkhardt, D. Westrup, C.M. Kirchmaier, H.K. Breddin & S. Harder*

Therapeutics

327 Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids: *D.A. Hesselink, H. Ngyuen, M. Wabbijn, P.J.H.S. Gregoor, E.W. Steyerberg, I.C. van Riemsdijk, W. Weimar & T. van Gelder*

Short reports

331 Allele and genotype frequency of *CYP2C19* in a Tamilian population: *C. Adithan, N. Gerard, S. Vasu, J. Rosemary, C.H. Shashindran & R. Krishnamoorthy*

334 The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment: *A. Annas, K. Carlström, G. Alván & A. AL-Shurbaji*

337 Interferon-β treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity: *K. Hellman, E. Roos, A. Österlund, A. Wahlberg, L.L. Gustafsson, L. Bertilsson & S. Fredrikson*

341 Identification of a novel splice-site mutation in the CYP1A2 gene: *D. Allorge, D. Chevalier, J.-M. Lo-Guidice, C. Cauffiez, F. Suard, P. Baumann, C.B. Eap & F. Broly*

Book reviews

345 Introduction to Drug Metabolism (Third Edition): *F. Kamali*

345 The Forensic Pharmacology of Drugs of Abuse: *R.J. Flanagan*

Volume 56, Number 4, October 2003

Editor's View

347 Features of this month's *Journal*: *J.K. Aronson*

Editorial

349 The BPS web site for Continuing Professional Development in Clinical Pharmacology and Therapeutics: *J. Mucklow, N. Baber, S. Maxwell & M. Pirmohamed*

Reviews

351 Evaluation of new therapies for inflammatory bowel disease: *E. Carty & D.S. Rampton*

362 Evaluation of drug treatment in irritable bowel syndrome: *N.J. Talley*

Pharmacokinetics

370 Population pharmacokinetics of liposomal daunorubicin in children: *G. Hempel, D. Reinhardt, U. Creutzig & J. Boos*

Pharmacodynamics

378 Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?: *S. Freudenthaler, P. Benöhr, A. Grenz, T. Selzer, T. Schmidt, K. Mörike, H. Osswald & C.H. Gleiter*

388 Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin: *A. Purohit, M. Melac, G. Pauli & N. Frossard*

Pharmacokinetics and Pharmacodynamics

395 Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects: *W.-C. Liao, O. Vesterqvist, C. Delaney, M. Jemal, I. Ferreira, N. Ford, B. Swanson & H. Uderman*

407 Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction: *R. Bruno, P. Baille, S. Retout, N. Vivier, C. Veyrat-Follet, G.-J. Sanderink, R. Becker & E.M. Antman*

Pharmacogenetics

415 Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes: *K. Herrlin, N. Yasui-Furukori, G. Tybring, J. Widén, L.L. Gustafsson & L. Bertilsson*

422 Leukotriene C_4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma: *G.P. Currie, J.J. Lima, J.E. Sylvester, D.K.C. Lee, W.J.R. Cockburn & B.J. Lipworth*

Drug Interactions

427 Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects: *M. Niemi, J.T. Backman, M. Neuvonen & P.J. Neuvonen*

Drug Metabolism

433 Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver: *Z.E. Wilson, A. Rostami-Hodjegan, J.L. Burn, A. Tooley, J. Boyle, S.W. Ellis & G.T. Tucker*

Clinical Toxicology

441 Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity: *G.K. Isbister, L.P. Hackett, A.H. Dawson, I.M. Whyte & A.J. Smith*

Short reports

451 Chest pain during use of bupropion as an aid in smoking cessation: *L. de Graaf & W.L. Diemont*

453 Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions: *G.O. Kokwaro, B.R. Ogutu, S.N. Muchohi, G.O. Otieno & C.R.J.C. Newton*

Book reviews

458 Antidotes: Principles and Clinical Applications: *R.J. Flanagan & A.L. Jones*

458 HMG-Co reductase inhibitors: *G. Schmitz & M. Torzewski*

Letters to the Editors

460 Statins and the risk of idiopathic venous thromboembolism: *J.G. Ray & M.M. Mamdani*

461 Author's response to letter from Ray *et al.*: *C.-C. Yang & S.S. Jick*

463 Errata

465 Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 10 October 2003

Volume 56, Number 5, November 2003

Editors' View

475 Features of this month's *Journal*: *J.K. Aronson*

Reviews

477 Pathology of drug-associated gastrointestinal disease: *A.B. Price*

483 Biopsy assessment of drug efficacy in the gastrointestinal tract: *M.M. Walker*

489 Dose estimation for children: *N. Baber & D. Pritchard*

Pharmacodynamics

494 Comparison of combination inhalers *vs* inhaled corticosteroids alone in moderate persistent asthma: *D.K.C. Lee, C.M. Jackson, G.P. Currie1, W.J. Cockburn & B.J. Lipworth*

501 Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function: *P.V. Dicpinigaitis & Y.E. Gayle*

505 Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man: *M.R. Downham, T.R. Auton, A. Rosul, H.L. Sharp, L. Sjöström, A. Rushton, J.P. Richards, T.G.K. Mant, S.M. Gardiner, T. Bennett & J.F. Glover*

513 The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension: *D. Patterson, J. Webster, G. McInnes, A. Brady & T. MacDonald*

Pharmacokinetics and Pharmacodynamics

520 Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients: *E.B. Belldina, M.Y. Huang, J.A. Schneider, R.C. Brundage & T.S. Tracy*

Drug Metabolism

526 Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human: *N. Cazali, A. Tran, J.M. Treluyer, E. Rey, P. d'Athis, J. Vincent & G. Pons*

537 An *in vitro* interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug: *T. Iwasa, H. Sano, A. Sugiura, N. Uchiyama, K. Hara, H. Okochi, K. Nakagawa, T. Yasumori & T. Ishizaki*

Drug Distribution

545 Free and bound propofol concentrations in human cerebrospinal fluid: *A.L. Dawidowicz, R. Kalitynski & A. Fijalkowska*

551 Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques: *L. Sasongko, K.M. Williams, R.O. Day & A.J. McLachlan*

Therapeutics

562 Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C: *S. Brien, G. Lewith & T. Bryant*

Prescribing

569 Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study: *J.A. Kaye, B.D. Bradbury & H. Jick*

Short reports

576 Quinine intoxications reported to the Scottish Poisons Information Bureau 1997–2002: a continuing problem: *N.J. Langford, A.M. Good, W.J. Laing & D.N. Bateman*

Book reviews

579 Drugs Handbook 2003: *M.J. Kendall*

579 Principles of Clinical Pharmacology: *M. Schacter*

Letters to the Editors

581 Neonatal intraventricular haemorrhage associated with maternal use of paroxetine: *Y.C.M. Duijvestijn, M.D. Kalmeijer, A.L.M. Passier, P. Dahlem & F. Smiers*

583 Serum sickness-like reaction associated with clopidogrel: *E.J. Phillips, S.R. Knowles & N.H. Shear*

584 Errata

Volume 56, Number 6, December 2003

Editors' View

585 Nurse prescribers & reporters: *J.K. Aronson*

Reviews

588 Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications: *N.R. Labiris & M.B. Dolovich*

600 Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications: *N.R. Labiris & M.B. Dolovich*

613 The epidemiology of self-poisoning in the UK: *D.R. Camidge, R.J. Wood & D.N. Bateman*

620 Nitrate tolerance and the links with endothelial dysfunction and oxidative stress: *K.E. Fayers, M.H. Cummings, K.M. Shaw & D.W. Laight*

Pharmacokinetics

629 Population pharmacokinetics of ceftazidime in burn patients: *E. Dailly, M. Pannier, P. Jolliet & M. Bourin*

635 Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route: *A. Sharabi, E. Cohen, J. Sulkes & M. Garty*

639 Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, *CYP2D6* genotype and formulation-dependent bioavailability: *T. Kerbusch, U. Wählby, P.A. Milligan & M.O. Karlsson*

Pharmacogenetics

653 Genetic polymorphisms of *CYP2C9* and *CYP2C19* in the Beninese and Belgian populations: *A.C. Allabi, J.-L. Gala, J.-P. Desager, M. Heusterspreute & Y. Horsmans*

Pharmacovigilance

658 The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme: *S. Sri Ranganathan, J.E. Houghton, D.P. Davies & P.A. Routledge*

Drug Disposition

664 Differential binding of disopyramide and warfarin enantiomers to human α_1-acid glycoprotein variants: *T. Nakagawa, S. Kishino, S. Itoh, M. Sugawara & K. Miyazaki*

Drug Interactions

670 Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin: *C.R. Kumana, M.K.L. Tong, C.-S. Li, I.J. Lauder, J.S.K. Lee, M. Kou, T. Walley, A. Haycox & T.M. Chan*

679 Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity: *S. Härtter, A. Nordmark, D.-M. Rose, L. Bertilsson, G. Tybring & K. Laine*

683 Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial: *A. Pfrunder, M. Schiesser, S. Gerber, M. Haschke, J. Bitzer & J. Drewe*

Short reports

691 Bioavailability of dexmedetomidine after extravascular doses in healthy subjects: *M. Anttila, J. Penttilä, A. Helminen, L. Vuorilehto & H. Scheinin*

Book review

694 Clinical Pharmacology: *G. Shenfield*

Letters to the Editors

695 Lead poisoning by self-administration in an exposed worker: *L. Astudillo, O. Guillard, L. Sailler, F. Rigal, B. Couret & E. Arlet-Suau*

696 Different effects of simvastatin and pravastatin on adrenal sensitivity to angiotensin II: *K.-I. Sugimoto & A. Fujimura*

698 Announcement

699 Indices for Volume 56